Anti-Rheumatic Drugs - Tanzania | Statista Market Forecast

The Anti-Rheumatic Drugs market in Tanzania is anticipated to experience substantial growth in the coming years.
According to projections, the market's revenue is expected to reach US$5.30m in 2024.
Furthermore, it is estimated that the market will witness an annual growth rate of 1.63% between 2024 and 2029, leading to a market volume of US$5.74m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market.
In 2024, United States is projected to generate a revenue of US$34.70bn.
This showcases the significant presence and market dominance of the United States in this particular market.
Tanzania's demand for affordable anti-rheumatic drugs is increasing rapidly due to the rising prevalence of rheumatoid arthritis in the country.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Tanzania has been steadily growing over the years, driven by a combination of factors such as increasing prevalence of rheumatoid arthritis, rising awareness about the disease, and the availability of affordable treatment options.

Customer preferences: Patients suffering from rheumatoid arthritis in Tanzania prefer to be treated with a combination of medication and non-pharmacological therapies such as exercise and physical therapy. While there is a preference for conventional disease-modifying antirheumatic drugs (DMARDs), there is also a growing demand for biologic DMARDs due to their efficacy in treating the disease.

Trends in the market: The Anti-Rheumatic Drugs market in Tanzania is witnessing a shift towards biologic DMARDs due to their effectiveness in treating rheumatoid arthritis. This trend is driven by increasing awareness about the disease and the availability of affordable biologic DMARDs. Additionally, the market is also witnessing a rise in the number of local manufacturers of Anti-Rheumatic Drugs, which is expected to drive down the cost of treatment.

Local special circumstances: The healthcare infrastructure in Tanzania is still developing, and there is a shortage of rheumatologists and other healthcare professionals who are trained in treating rheumatoid arthritis. This has led to a delay in diagnosis and treatment, which has resulted in a higher prevalence of the disease. However, the government has taken steps to address this issue by increasing the number of healthcare professionals and investing in healthcare infrastructure.

Underlying macroeconomic factors: Tanzania has a growing economy, which has led to an increase in healthcare spending. Additionally, the government has implemented policies to promote local manufacturing of pharmaceuticals, which has led to a rise in the number of local manufacturers of Anti-Rheumatic Drugs. This has resulted in increased competition and lower prices, making treatment more affordable for patients. However, the market is still heavily reliant on imports, which makes it vulnerable to fluctuations in the global market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.